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Erythropoietin (EPO), a sialoglycoprotein that regulates the circu-
lating erythroid mass, is produced in the kidneys in response to
hypoxia by a regulated feedback mechanism. Administration of
recombinant human erythropoietin (rHuEPO) has been shown to
be effective in amelioration of the anaemia associated with renal
disease and the anaemia associated with chemotherapy (Platanias
et al, 1991; Miller et al, 1992; Cascinu et al, 1994; Henry and
Abels, 1994; Ludwig et al, 1995; Del Mastro et al, 1997; Glaspy et
al, 1997; Henry, 1998; Maraveya and Pettengell, 1998). 
Novel erythropoiesis stimulating protein (NESP, darbepoetin
alfa) was developed recently and exhibits extended pharmaco-
kinetic properties compared with rHuEPO. NESP, which has 8
more sialic acids than rHuEPO, and is therefore biochemically
distinct, has an increased terminal half-life in animal models and
in patients undergoing peritoneal dialysis (Macdougall et al, 1999;
Macdougall, 2000). Increasing the half-life of active drug may
offer a potential clinical advantage by allowing less frequent
dosing. 
It was anticipated that the pharmacokinetics of NESP in patients
with cancer would be similar to those observed for patients with
renal failure. This hypothesis was based on preclinical studies that
indicated that the clearance pathway of NESP, like rHuEPO, is
primarily by desialylation and elimination through the liver
(Spivak and Hogans, 1989). However, patients with cancer have
many confounding factors, including the administration of
chemotherapy and subsequent myelosuppression, that may have
unanticipated effects on pharmacokinetic parameters. In addition,
the depletion of responding erythroid precursors by the cytotoxic
effects of chemotherapy may result in a higher dosing requirement
than is needed in the setting of renal failure. Although the pharmaco-
kinetics of rHuEPO in dialysis patients have been described, no
such report exists for the pharmacokinetics of rHuEPO in patients
with cancer (Macdougall et al, 1989). The current study was
undertaken to evaluate the pharmacokinetic profile of NESP
administered to cancer patients receiving multiple cycles of
chemotherapy and to compare the pharmacokinetics of single- and
multiple-dose administration of NESP through 3 cycles of
chemotherapy. This report describes results from the first 15
patients treated. 
MATERIALS AND METHODS 
Patients 
Before enrolling patients in the study, independent ethics
committee approval and written patient informed consent were
obtained. Patients with non-myeloid malignancies were eligible to
enrol if they were scheduled to receive cyclic chemotherapy at 
3-week intervals for at least 3 more cycles and had a haemoglobin
value ≤ 1 1 . 0gd l –1, a life expectancy of at least 3 months, and an
Eastern Cooperative Oncology Group (ECOG) performance status
of 0 to 2. Other eligibility requirements included adequate renal
(creatinine ≤ 2.0 mg dl–1) and hepatic (bilirubin ≤ 1.5 times upper
limit of normal range) function. Patients were to be excluded from
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This study was supported by Amgen Inc, Thousand Oaks, California. the study if they had a history of primary haematologic disorders
that could cause anaemia; clinically significant disease or dysfunc-
tion of the cardiovascular, pulmonary, endocrine, neurological,
gastrointestinal or genitourinary systems; primary or metastatic
malignancy involving the central nervous system; uncontrolled
hypertension; seizures; or iron deficiency. 
Twenty to 30 patients were to be enrolled from eight centres.
Patients who responded to treatment could elect to continue NESP
treatment until completion of their course of chemotherapy (a
maximum of 24 weeks). Data from this optional portion of the
study concerning haemoglobin response are not presented in this
report, but adverse event data are reported from time of enrolment
to end of follow-up period. 
Study design 
This was an open-label study of NESP (darbepoetin alfa, 
ARANESPTM, Amgen Inc, Thousand Oaks, CA) administered by
weekly subcutaneous injection to patients receiving multiple
cycles of chemotherapy. This report includes the results of the first
15 patients enrolled, who had completed study drug administration
by November 2000. Patients had a medical history and physical
examination, including ECOG performance status determination,
at screening. Endogenous EPO levels were measured on study day
1 before administration of NESP. Patients received NESP 2.25 mcg
kg–1 wk–1, under the supervision of a physician, as a single sub-
cutaneous injection immediately before receiving chemotherapy,
and through 3 cycles of chemotherapy, which were at least 
3 weeks apart (Part A). The first dose of NESP was administered
on day 1 of the next cycle of chemotherapy after enrolment.
Patients who responded to treatment could elect to continue NESP
treatment until completion of their course of chemotherapy to a
maximum of 24 weeks (Part B). 
Blood samples were collected over a 7-day period on week 1 of
chemotherapy cycles 1 and 3 to determine the pharmacokinetic
profile of NESP. Blood samples for pharmacokinetic analyses were
drawn before NESP administration and at 6, 24, 32, 48, 72, 96 and
120 hours after NESP administration. In addition, weekly pre-
dose/trough (168 hour) samples and additional 48-hour post-dose
(cycle 2) samples were collected. Samples for complete blood count
(including reticulocytes) were collected at screening and weekly
during the study to assess haemoglobin response. Blood samples for
detection of antibody formation were collected before study drug
administration on day 1 of cycle 1 (baseline) and on day 1 of cycle 3
before administration of NESP and chemotherapy. Additional
samples for the detection of antibody formation were collected
throughout the optional treatment phase and at the end of study. 
The frequency of red blood cell transfusions was recorded.
Adverse events and determinations of serum antibodies to NESP
were monitored. All patients had a 4-week follow-up period after
the end of study drug administration. 
Dose adjustments 
If, during the study, a patient’s haemoglobin value increased by
³ 2 . 0gd l –1 over any 4-week period in the absence of red blood cell
transfusion, the dose of NESP was reduced by 50%. In addition, if
the patient’s haemoglobin value increased to > 15.0 g dl–1 (for
men) or > 14.0 g dl–1 (for women), the dose of NESP was withheld
until the haemoglobin value decreased to ≤ 12.0 g dl–1; study drug
was then resumed at 50% of the previous dose level. 
Patients who did not respond (i.e. had ≤ 1gd l –1 change from
baseline) after 6 weeks (2 cycles) were to have the dose of NESP
increased to 4.5 mcg kg–1 wk–1. 
Determination of EPO and NESP serum concentrations 
The assays to determine endogenous EPO serum concentrations
and NESP serum concentrations were conducted by MDS
Pharma Services (Quebec, Canada) using a standard commer-
ical ELISA kit. The antibodies in the Quantikine rHuEPO kit
(R & D Systems, Minneapolis, MN) are able to detect both EPO
and NESP. The ELISA assay uses a monoclonal antibody immo-
bilized to the plate and a sandwich polyclonal antibody for
detection. The colourimetric read-out (optical density) was
measured at 450 to 650 nm, wherein the colour change was
directly proportional to the amount of endogenous EPO or
NESP in the sample. Each sample was run in duplicate with 7
standards and 5 quality-control samples on the plate; these
samples were prepared in buffer. Specimen diluent was used to
dilute samples as needed. 
For endogenous EPO, the standard curve ranged from 10.080 to
380.800 mU ml–1, with a lower limit of quantification of 12.000
mU ml–1. The assay has been validated, demonstrating accuracy
(intra-assay: 98% to 114%; interassay: 98% to 108%, where
values are percentage of nominal concentration of quality
controls), precision (intra-assay: 4% to 14%; interassay: 2% to
10%, where values are percent coefficient of variation for quality
control), and stability (five freeze-thaw cycles). Of the tested
substances, (recombinant human [rHu] interleukin-3 [rHuIL-3],
rHuIL-6, rHu granulocyte-macrophage colony-stimulating factor
[rHuGM-CSF], r-metHuG-CSF, and NESP), only NESP cross-
reacted in the assay. 
For NESP, the standard curve ranged from 0.125 to 5.000 ng ml–1,
with a lower limit of quantification of 0.140 ng ml–1. The assay
has been validated, demonstrating accuracy (intra-assay: 107%
to 112%; interassay: 105% to 110%, where values are percentage
of nominal concentration of quality controls), precision (intra-
assay: 3% to 17%; interassay: 3% to 6%, where values are
percent coefficient of variation for quality control), and stability
(five freeze-thaw cycles). Of the tested substances (rHuIL-3,
rHuIL-6, rHuGM-CSF, r-metHuG-CSF and rHuEPO), only
rHuEPO cross-reacted in the assay. 
Pharmacokinetic analysis 
All values that were below the lower limit of quantification
(generally 0.14 ng ml–1 for NESP) were recorded as zero. In all
cases, measured NESP serum concentrations were baseline
corrected to account for the presence of endogenous EPO, which
cross-reacts in the NESP assay. When baseline correction yielded
a negative value, this value was recorded as zero. This method of
correction assumes that the endogenous EPO concentration
remains constant over time for a given individual. 
Pharmacokinetic analysis was performed (WinNonLin Pro,
Pharsight, Palo Alto, CA) using non-compartmental analysis tech-
niques. The pharmacokinetic parameters determined were
maximum observed concentration (Cmax) and the time at which this
concentration occurred (Tmax). Relative clearance (CL/F) was
determined from (AUC(0–¥)/Dose), and terminal half-life (t1/2,z) was
estimated by log-linear regression of the terminal portion of the
curve. 
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The number and proportion of patients achieving haemoglobin
response at the end of 6 weeks (change from baseline of > 1.0 g dl–1
in the absence of red blood cell transfusions) and at the end of the
third chemotherapy cycle (change from baseline of ³ 2 . 0gd l –1 in
the absence of red blood cell transfusions) were tabulated. Exact
95% confidence intervals are given for the proportions. 
The number and proportion of men reaching a haemoglobin
concentration of > 15.0 g dl–1 and the number and proportion of
women reaching a haemoglobin concentration of > 14.0 g dl–1 are
presented. Summary statistics (mean, standard deviation (SD),
median, quartiles, minimum and maximum) were tabulated for the
maximum haemoglobin concentration achieved by the end of the
third chemotherapy cycle and the maximum change from baseline
over the same period. 
The patient incidence of adverse events was calculated by body
system and preferred term for events that started or worsened on or
after the day of study drug administration and before or at the end
of follow-up. Notable results are presented here; the complete
tabulation is on file at Amgen Ltd. 
RESULTS 
Patient demographics and disposition 
Patient characteristics and demographic information are given in
Table 1. Available data from 15 patients are included for evalua-
tion of haemoglobin response, and data from 15 and 7 patients are
included for pharmacokinetic analysis for cycle 1 and cycle 3,
respectively. 5 patients discontinued study; 2 because of death due
to disease progression (reported by the investigator as unrelated to
NESP), 1 because of an adverse event of asthenia (reported by the
investigator as unrelated to NESP) and 2 for administrative
reasons. 
Results of pharmacokinetic analysis 
Baseline endogenous EPO concentrations were determined using
both the EPO and NESP assays. The mean (standard deviation
(SD)) endogenous EPO concentrations, assessed against an EPO
standard curve, were 67.6 (69.4) mU ml–1 (n = 15). The minimum
and maximum values were 0.00 and 235 mU ml–1, respectively.
When assessed using the NESP standard curve, mean (SD)
prestudy cross-reactivity in the assay was 0.774 (0.727) ng ml–1
(n = 15). 
Summary statistics for non-compartmental pharmacokinetic
parameters after single doses (week 1, cycle 1) are provided in
Table 2. Cycle 1, week 1 intensive profiles were determined for 15
patients, but only 8 of these profiles were evaluable. In 5 of 15
patients, the 168-hour sampling period was insufficient to accu-
rately determine extrapolated parameters (percentage extrapolated
> 25%). In 2 additional patients, the terminal phase could not be
determined because the serum NESP concentrations did not
decrease consistently. Therefore, values for terminal half-life (t1/2, z)
and relative clearance (CL/F) were estimated for 8 patients.
Additionally, 1 of the 8 patients for whom all pharmacokinetic
parameters were estimated had extremely low serum NESP
concentrations compared with the other patients, resulting in low
Cmax and high CL/F. For this reason, all summary statistics were
calculated with and without this patient. 
Data are presented as mean (SD). After single-dose (cycle 1)
administration (2.25 mgk g –1), the mean maximal NESP concentra-
tion of 8.44 (5.3) ng ml–1 occurred at 85.1 (22.3) hours after NESP
administration, the terminal half-life ranged from 20.7 to 54.2
hours (33.1 (11.1) hours), and the relative clearance ranged from
2.37 to 22.4 ml h–1 kg–1 (6.03 (6.66) ml h–1 kg–1) (data not shown).
Exclusion of the 1 patient with low pharmacokinetic parameters
resulted in mean maximal concentration of 8.96 (5.10) ng ml–1 that
occurred at 86.1 (22.8) hours after NESP administration, a
terminal half-life that ranged from 20.7 to 54.2 hours (32.6
(11.8) hours), and a relative clearance that ranged from 2.37 to
5.49 ml h–1 kg–1 (3.7 (1.0) ml h–1 kg–1). 
Baseline-corrected weekly trough concentrations before the
administration of NESP 2.25 mcg kg–1 wk–1 are provided in Figure
1 for patients receiving chemotherapy every 3 weeks. Within each
chemotherapy cycle, the trough concentrations varied, increasing
from minimum values at week 1 to maximum values at week 2
Pharmacokinetics of NESP with chemotherapy 13
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Table 1 Demographics and baseline characteristics for patients receiving
NESP 2.25 mcg kg–1 wk–1 who completed the study by the November 2000
interim analysis 
NESP (2.25 mcg kg–1 wk–1) 
Number of patients enrolled, n 15 
Age (years) 
Mean (SD) 61.3 (12.7) 
Sex, n (%) 
Women 8 (53%) 
Men 7 (47%) 
Race 
White 15 (100%) 
Weight (kg) 
Mean (SD) 67.8 (14.0) 
Tumour type, n (%) 
Non-Hodgkin’s lymphoma 3 (20%) 
Hodgkin’s lymphoma 2 (13%) 
Lung 3 (20%) 
Breast 2 (13%) 
Gastrointestinal 2 (13%) 
Gynaecologic 2 (13%) 
Genitourinary 1 (6.7%) 
ECOG performance status 
0 6 (40%) 
1 7 (47%) 
2 2 (13%) 
Baseline Hgb (g dl–1) 
Mean (SD) 9.6 (0.8) 
Minimum, maximum 8.3, 10.5 
ECOG = Eastern Cooperative Oncology Group; Hgb = haemoglobin; 
SD = standard deviation. 
Table 2 Summary statistics for non-compartmental pharmacokinetic
parameters, week 1 of cycle 1. Data from one patient with extremely low
concentrations have been omitted 
Parameter Tmax Cmax t1/2, z CL/F 
(hours) (ng ml–1) (hours) (ml h–1 kg–1) 
Mean 86.1 8.96 32.6 3.70 
SD 22.8 5.10 11.8 0.995 
% CV 26.5 56.9 36.4 26.9 
n 14 14 7 7 
Tmax = time to maximum concentration; Cmax = maximum serum
concentration; t1/2, z = terminal half-life; CL/F = relative clearance. (approximately 3-fold increase) and then declining on week 3. As
expected, a general trend of increasing trough concentrations over
time (cycle 3 demonstrating an approximate 2-fold increase over
cycle 1) was observed as steady-state concentrations were
achieved. 
Mean (SD) NESP serum concentration–time profiles for cycle 1
and cycle 3 after administration are compared in Figure 2. For
most patients, the serum concentration–time profiles were typical
of those seen after subcutaneous dosing: a slow increase to peak
concentration (range of single dose: 48 to 123 hours post-dose)
and subsequent monophasic decline. Comparison of the mean
profiles after single and multiple dosing indicated that NESP phar-
macokinetics do not alter substantially after multiple dosing, given
the variability in the dataset. However, the higher concentrations at
the earlier time points during cycle 3 are a result of increasing
concentrations to steady state. 
Full non-compartmental analysis was not conducted on the
cycle 3 profiles because of inadequate sampling time (168 hours)
and the extended elevation of the serum concentrations. However,
comparison of mean (SD) maximal concentrations for cycle 1
(8.44 (5.3) ng ml–1, n = 15) and cycle 3 (10.3 (8.0) ng ml–1, n = 7)
indicates a slight increase in concentration, reflective of increase
in steady state. 
The mean (SD) change of haemoglobin values from baseline
was 2.3 (1.2) g dl–1 at the end of Part A and 1.2 (1.1) at the end of
4 weeks (Table 3). Haemoglobin values were monitored and the
dose of NESP was modified during the study, depending on the
haemoglobin response observed. Only 1 patient exceeded pre-
determined threshold levels for discontinuation of study drug: a
woman with a haemoglobin value > 14 g dl–1. 
Safety 
The type and incidence of adverse events reported in this study are
consistent with the population being studied. No unexpected
trends in the type, incidence or severity of adverse events
were observed. The most frequently reported adverse events were
asthenia (53%), vomiting (47%), nausea (47%) and fever (40%). 
Two of the 15 patients (13%) died of disease progression; both
deaths were reported by the investigator to be unrelated to NESP
administration. One of these patients died after completing 10
weeks of study drug administration, and 1 died on study after week
5 of study drug administration period. Both of these patients are
included in the safety analysis. 
Six patients reported adverse events meeting the International
Conference on Harmonisation (ICH) definition of serious,
including neutropenic fever, shortness of breath, congestive heart
failure, angina, deep vein thrombosis and erysipelas. None of these
serious adverse events were considered by the investigator to be
related to NESP. No patients were identified as having developed
antibodies to NESP. 
DISCUSSION 
This preliminary pharmacokinetic analysis of NESP in patients
with non-myeloid malignancies indicates that NESP is slowly
absorbed after subcutaneous administration, reaching peak
concentrations approximately 85 hours after NESP administration.
In the evaluable sub-group, NESP exhibits low relative clearance
(mean 3.7 ml h–1 kg–1) and a long terminal half-life (mean 32.6
hours). The inability to estimate the terminal phase during the 
168-hour sampling period for a number of patients biases the
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Figure 1 Mean (standard deviation) baseline-corrected serum NESP trough concentrations (ng ml–1) for weekly subcutaneous administration of 2.25 mcg kg–1
wk–1 NESP for patients with 3-week chemotherapy cycles. Error bars are one standard deviation actual estimated values toward those patients with a shorter
terminal half-life. Hence, the subjects for whom the NESP serum
concentration–time profiles were evaluable over the 168-hour
interval (8 of 15) may represent a sub-group of the entire pop-
ulation. A longer sampling duration and dosing interval would be
required to accurately estimate the half-life in patients with cancer
receiving chemotherapy in whom NESP exhibits a longer terminal
half-life, i.e. a second sub-group whose clearance and/or absorp-
tion is very slow. Overall, increases in serum concentrations reflect
increases to steady-state values, as verified by pharmacokinetic
modelling. These results suggest that it may be possible to admin-
ister NESP at less frequent intervals and still maintain the
observed biologic effect. Studies are ongoing to assess the efficacy
of NESP at less frequent dose schedules.
The pharmacokinetic properties of NESP, with both intravenous
and subcutaneous dosing, have previously been determined in
patients with chronic renal failure (Macdougall et al, 1999). After
subcutaneous administration of a single dose of NESP
0.5 mcg kg–1, mean (SD) peak serum concentrations of 0.94 (0.1)
ng ml–1 were observed at approximately 50 hours after dosing. The
terminal half-life was 48.8 (5.2) hours, and relative clearance
(calculated using mean intravenous clearance and mean subcuta-
neous bioavailability) was 4.3 ml h–1 kg–1. The pharmacokinetics
of NESP in oncology patients have been studied in a small number
of patients in a dose-ranging study (Glaspy et al, 2000). The
terminal half-life of NESP (in 5 patients after a single subcuta-
neous dose of 0.5, 1.5 or 4.5 mcg kg–1 NESP) ranged from 30.1 to
45.6 hours, and the relative clearance ranged from 1.86 to
4.01 ml h–1 kg–1. These limited data span the values obtained in the
current study and those obtained in studies in the chronic renal
failure setting. 
The differences in terminal half-life between the patient pop-
ulation with chronic renal failure and the current study most likely
reflect the bias towards lower estimates in the current study, espe-
cially since the relative clearance values are similar. However, the
possibility that the pharmacokinetics of NESP differ somewhat
between patients with chronic renal failure and patients with
cancer receiving chemotherapy cannot be excluded. These differ-
ences could result from the disease state itself or from the
concomitant administration of chemotherapy. The observation in
the current study that NESP trough serum concentrations varied
within a chemotherapy cycle indicated the possible impact of
Pharmacokinetics of NESP with chemotherapy 15
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Table 3 Haemoglobin response 
NESP (2.25 mcg kg-1 wk-1) 
Number of patients enrolled, n 15 
Mean (SD) change in Hgb by week 4
g dl–1 1.2 (1.1) 
Mean (SD) change in Hgb by end of study Part A
g dl–1 2.3 (1.2) 
Total number of women, n 8 
Number with Hgb > 14 g dl–1 1 (13%) 
Total number of men, n 7 
Number with Hgb > 15 g dl–1 0 (0%) 
Hgb = haemoglobin; SD = standard deviation. 
18
16
14
12
10
8
6
4
2
0
0
24 48 72 96 120 144 168
B
a
s
e
l
i
n
e
-
c
o
r
r
e
c
t
e
d
 
s
e
r
u
m
 
N
E
S
P
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
 
m
l
-
1
)
Time (hours)
Figure 2 Mean (standard deviation) baseline-corrected serum NESP concentration (ng ml–1) after weekly subcutaneous administration of 2.25 mcg kg–1 wk–1
NESP, week 1 of cycle 1 and week 1 of cycle 3. Solid circles, cycle 1, n = 14 to 15; open circles, cycle 3, n = 7 to 9. Error bars are one standard deviation myelosuppression on the pharmacokinetics of NESP. Within a
cycle, the week 1 values (immediately before both NESP and
chemotherapy administration) were the lowest of any cycle,
whereas the week 2 values (1 week after chemotherapy) were the
highest of any cycle. These observations point to the possibility of
bone marrow involvement in either the clearance or distribution of
NESP, perhaps through the EPO receptor on the erythroid precur-
sors. Immediately after chemotherapy, the pool of erythroid
precursors decreases, allowing more NESP to be circulating and
thus measurable. Additional preclinical studies are ongoing to
elucidate these mechanisms, as well as clinical studies in patients
with cancer not receiving chemotherapy. The possibility of bone
marrow involvement in the catabolism of endogenous EPO
(Piroso et al, 1989) and an observed increase in endogenous EPO
due to myeloablation (Piroso et al, 1989; Sawabe et al, 1996) have
been previously published. 
The haemoglobin response of patients receiving NESP in this
study suggests that a dose of 2.25 mcg kg–1 wk–1 is an effective
initial dose in this population and that modification of the dosing
schedule, depending upon the haemoglobin value, allowed an
appropriate response to be maintained over the course of the
chemotherapy administered. The mean changes in haemoglobin
observed at week 4 and at the end of Part A of the study compare
favourably with data cited in the literature for rHuEPO as well as
with data presented in another paper in this supplement (Glaspy
et al, 2001). 
The available safety data from this study suggest that NESP
2.25 mcg kg–1 wk–1 is well tolerated in this population. The adverse
events reported in this study are typical for this patient population
with advanced malignancy receiving multicycle chemotherapy, and
their pattern, incidence and severity are similar to those labelled for
rHuEPO. No antibodies to NESP were detected. 
This study continues to enrol patients to further explore the
pharmacokinetics of NESP after both subcutaneous and intra-
venous administration. Based on these preliminary findings, the
pharmacokinetic parameters of NESP suggest that it has a low
clearance and a prolonged half-life that may allow for infrequent
administration of this agent to patients with cancer who are
receiving multicycle chemotherapy. 
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